| 000 | 01621 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250513190444.0 | ||
| 264 | 0 | _c19990806 | |
| 008 | 199908s 0 0 eng d | ||
| 022 | _a0008-543X | ||
| 024 | 7 |
_a10.1002/(sici)1097-0142(19990801)86:3<514::aid-cncr21>3.0.co;2-9 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSweeney, C J | |
| 245 | 0 | 0 |
_aA Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium. _h[electronic resource] |
| 260 |
_bCancer _cAug 1999 |
||
| 300 |
_a514-8 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 |
_aCarcinoma, Transitional Cell _xdrug therapy |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aDrug Evaluation |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIfosfamide _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPaclitaxel _xadministration & dosage |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 |
_aUrologic Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aUrothelium |
| 700 | 1 | _aWilliams, S D | |
| 700 | 1 | _aFinch, D E | |
| 700 | 1 | _aBihrle, R | |
| 700 | 1 | _aFoster, R S | |
| 700 | 1 | _aCollins, M | |
| 700 | 1 | _aFox, S | |
| 700 | 1 | _aRoth, B J | |
| 773 | 0 |
_tCancer _gvol. 86 _gno. 3 _gp. 514-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/(sici)1097-0142(19990801)86:3<514::aid-cncr21>3.0.co;2-9 _zAvailable from publisher's website |
| 999 |
_c10388060 _d10388060 |
||